

GLOBAL & USA CANCER BIOMARKER MARKET TO 2018

MARKET SIZE, SEGMENTATION, KEY
PLAYERS, SWOT ANALYSIS, INFLUENTIAL
TECHNOLOGIES & BUSINESS &
ECONOMIC ENVIRONMENTS



GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)

Table of Contents

1.0	Executive Summary	13
1.1	Objectives of Report	13
1.2	Data Sources and Methodology	15
1.3	Key Findings and Observations	15
1.3.1	What Makes Cancer Biomarkers so Important for the Healthcare Industry?	15
1.3.2	What Technologies are Used to Identify Novel Biomarkers?	16
1.3.3	Increase in Cancer Prevalence is Propelling the Oncogenic Biomarker Market	16
1.3.4	Global and US Economic Impact of Cancer	16
1.3.5	How Cancer Biomarkers are Revolutionizing Cancer Treatment	17
1.3.6	What are the most Significant and Strategic Cancer Biomarkers?	17
1.3.7	Global Biomarker Test Market Analysis	18
1.3.8	Global Cancer Biomarker Market Analysis	18
1.3.9	Oncology Biomarker Market Main Industry Players	19
1.3.10	Drivers, Restraints, Opportunities and Challenges of the Cancer Biomarker Market	19
2.0	Global Burden of Cancer	20
2.1	Global Cancer Statistics	20
2.2	Lung Cancer Globally	25
2.3	Lung Cancer Mutation Analysis	28
2.4	Colorectal (Bowel) Cancer Globally	29
2.5	Prostate Cancer Globally	31
2.6	Breast Cancer Globally	33
2.7	Global Economic Impact of Cancer	39
2.8	Cancer in the USA	40
2.9	Breast Cancer in the US	43
2.10	Lung Cancer in the US	44
2.11	Colorectal Cancer in the US	45
2.12	Prostate Cancer in the US	50
2.13	Skin Cancer in the US	52
3.0	Oncogenic Biomarkers – An Overview	54
3.1	Biomarker Discovery to Clinical Validation	56
3.2	Specific Technologies Used in Biomarker Discovery	57
3.2.1	Proteomics	57
3.2.2	Mass Spectrometry Based Technologies	57
3.2.3	Principles of Diagnostic Mass Spectrometry	58
3.2.4	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)	58
3.2.5	Nano LC-MS/MS	59
3.2.6	MALDI-TOF	59
3.3	Glycomics	60
3.4	Metabolomics	61
3.5	Peptidomics	62
3.5.1	Enzyme-Linked Immunosorbent Assay (ELISA)	62
3.6	Selected (Multiple) Reaction Monitoring	66
3.7	DNA Based Techniques	67
3.7.1	Microarrays	67
3.7.2	Small Molecule Real Time (SMRT) DNA Sequencing	69
3.7.3	Digital PCR	69
3.7.4	Next Generation Sequencing	70

3.7.5	Second-Generation Sequencing Platforms	71
3.7.6	Whole Genome Sequencing	71
3.7.7	Epigenomics	72
3.7.8	Bioinformatics and Next Generation Sequencing	72
3.7.9	Third Generation Sequencing	72
4.0	Biomarker Validation	73
4.1	Introduction	73
4.2	Phases of Biomarker Validation	73
4.3	Biomarker Validation and Clinical Trials	75
5.0	Current and Prospective Oncogenic Biomarkers	77
5.1	Catalogue of Somatic Mutations in Cancer (COSMIC)	77
5.2	P53 Transcription Factor Oncogenic Mutations	78
5.2.1	Current Clinical Trials Investigating P53 as an Oncogenic Biomarker	83
5.3	Epidermal Growth Factor Receptor (EGFR)	84
5.3.1	EGFR-Activating and Resistance Mutations	85
5.3.2	Clinically Validated Resistance Mechanisms to EGFR Inhibitors	86
5.3.3	Current Strategies to Defeat Resistance to EGFR-Mediated Cancer Therapeutics	87
5.4	BRCA- Mutant Cancers	87
5.5	PARP-Inhibitors are Making a Comeback	90
5.5.1	Olaparib – A Pipeline PARP-Inhibitor	90
5.5.2	Niraparib (MK4827) in Phase III trials	91
5.5.3	Rucaparib	91
5.5.4	Veliparib	91
5.5.5	Novel Biomarkers in the PARP-Inhibitor Response Pathway	92
5.6	PTEN – Current Leader in Pipeline Oncogenic Biomarkers	92
5.7	Ataxia Telangiectasia Mutated (ATM) – A Pipeline Target	93
5.8	TMPRSS2-ERG – A Promising Prostate Cancer Biomarker	94
5.9	MiR-17/92 Cluster – The Oncomir with Biomarker Potential	95
5.9.1	Altered MiR-17/92 Expression Correlates with Cancer Pathogenesis	95
5.9.2	MiR-17/92 Cluster and Colorectal Cancer	96
5.9.3	MiR-17/92 Cluster and Breast Cancer	96
5.9.4	MiR-17/92 Cluster and Ovarian Cancer	97
5.9.5	MiR-17/92 Cluster and Lung Cancer	97
5.9.6	MiR-17/92 Cluster and Renal Cancer	97
5.9.7	MiR-17/92 Cluster and Head and Neck Cancer	97
5.9.8	MiR-17/92 Cluster and Pancreatic Cancer	97
5.9.9	MiR-17/92 Cluster and Liver Cancer	98
5.9.10	MiR-17/92 Cluster and Acute Myeloid Leukaemia	98
5.9.11	MiR-17/92 Cluster and B-Cell Lymphoma	98
5.9.12	MiR-17/92 Cluster and B-Cell Chronic Lymphocytic Leukemia	98
5.9.13	Transcriptional Regulators of MiR-17/92 Cluster	98
5.9.14	Significant Molecular Targets of MiR-17/92	99
6.0	Cancer Biomarker Test Market Analysis 2013-2018	101
6.1	Economic Burden of Cancer Worldwide	101
6.2	Economic Burden of Cancer in the US	101
6.3	Global Biomarker Test Market Analysis	102
6.4	Oncology Biomarkers Dominate the Biomarker Market	103
6.5	Global Cancer Profiling Technology Market	105
6.6	Global Cancer Biomarker Market Analysis	105
6.7	Market Share of Oncology Market Within Total Biomarker Market	108
6.8	US Cancer Biomarker Market	108
6.9	Oncology Biomarker Market is Fuelled by Year-on-Year Expansion of Research Publications	109

6.10	Proteomic and Genomic Technologies are Preferred as Methods of Detection by End-Users	114
7.0	Oncology Biomarker Market Main Industry Players	115
7.1	23andMe	115
7.2	Affymetrix	116
7.3	Ambry Genetics	118
7.4	Astex Pharmaceuticals	119
7.5	Atossa Genetics	121
7.6	CuraGen	122
7.7	Celera Corporation (Quest Diagnostics)	122
7.8	Celldex Therapeutics	122
7.9	deCode Genetics (Amgen)	124
7.10	Foundation Medicine	124
7.11	Illumina	125
7.12	Genelex	126
7.13	Genomic Health	126
7.14	Myriad	126
7.15	Nodality	127
7.16	OriGene Technologies	130
7.17	Randox	130
7.18	Qiagen	131
8.0	Oncology Biomarker Market Products and Kits	133
8.1	Oncology Companion Diagnostic Tests	133
8.1.1	HER2 Tests in Breast Cancer Patients	133
8.2	23andMe	135
8.3	Affymetrix	139
8.4	Ambry Genetics	140
8.4.1	BRCAPlus	140
8.4.2	BreastNext	141
8.4.3	CancerNext	141
8.4.4	ColoNext	141
8.4.5	OvaNext	142
8.4.6	PancNext	142
8.4.7	RenalNext	142
8.4.8	Hereditary Diffuse Gastric Cancer Test	145
8.5	Astex Pharmaceuticals	150
8.6	Atossa Genetics	150
8.6.1	Mammary Aspirate Specimen Cytology Test (MASCT™)	150
8.6.2	ForeCYTE Breast Health Test (SM)	150
8.6.3	ArgusCYTE Breast Health Test(SM)	151
8.6.4	FullCYTE Breast Health Test	151
8.6.5	NextCYTE Breast Health Test	151
8.7	BioMerieux	151
8.7.1	THxID™ -BRAF Kit	151
8.8	Celera (Quest Diagnostics)	151
8.9	deCode Genetics	153
8.9.1	deCODE Breast Cancer™	153
8.9.2	deCODE Prostate Cancer™	153
8.9.3	deCODE AF™	153
8.9.4	deCODE Complete™	153
8.9.5	deCODE Cancer™	154
8.9.6	deCODE Services	154
8.10	Foundation Medicine	155
8.10.1	FoundationOne	155

8.10.2	FoundationOne Heme	155
8.11	Illumina	157
8.11.1	Illumina New-Generation Sequencing Technology	157
8.11.2	Illumina HiSeq 2500/1500	158
8.11.3	Illumina HiSeq 2000/1000	158
8.11.4	Genome Analyzer Iix	159
8.11.5	Illumina MiSeq	159
8.11.6	Illumina HiScanHQ	159
8.11.7	Illumina HiScan and iScan Array	159
8.12	Genelex	160
8.13	Genomic Health	160
8.13.1	Oncotype DX Breast Cancer Test	160
8.13.2	Oncotype DX Colon Cancer Test	161
8.13.3	Oncotype DX Prostate Cancer Assay	161
8.14	Myriad Genetics	163
8.14.1	BRACAnalysis®	163
8.14.2	Comprehensive BRACAnalysis®	165
8.14.3	BRACAnalysis® Rearrangement Test (BART)	165
8.14.4	Single Site BRACAnalysis®	165
8.14.5	Multisite 3 BRACAnalysis®	165
8.14.6	COLARIS®/COLARIS AP®	166
8.14.7	MELARIS®	166
8.14.8	PANEXIA®	166
8.14.9	OnDose®	167
8.14.10	PREZEON™	167
8.14.11	THERAGUIDE® 5FU	167
8.14.12	Prolaris®	167
8.15	Nodility	168
8.16	OriGene	168
8.16.1	TissueScan™ Cancer cDNA Arrays	168
8.17	Randox	172
8.17.1	Tumor PSA Marker Array	172
8.17.2	Tumor Marker Array 3	172
8.17.3	KRAS/ BRAF/PIK3CA Array	172
8.18	Qiagen	173
8.18.1	Genotyping Products	173
8.18.2	QIA-symphony Platform	175
8.18.3	Therascreen® EGFR RGQ PCR Kit	176
8.18.4	Therascreen KRAS RGQ PCR System	176
8.18.5	Therascreen® IDH1/2 test	176
8.19	Roche	177
8.19.1	Cobas® EGFR Mutation Test	177
9.0	Market Participant Financial and Business Strategy Analysis	178
9.1	23andMe	178
9.2	Affymetrix	180
9.3	Astex Pharmaceuticals (Otuska Pharamceutical)	189
9.4	Atossa Genetics	192
9.5	BioMerieux	195
9.6	Celera (Quest Diagnostics)	200
9.7	Celldex Therapeutics	206
9.8	deCode Genetics (Amgen)	207
9.9	Foundation Medicine	208
9.10	Illumina	210

9.11	Genelex	213
9.12	Genomic Health	213
9.13	Myriad	214
9.14	Nodality	218
9.15	Qiagen	220
10.0	Objective Business and Strategic Analysis of the Cancer Biomarker Market	225
10.1	Drivers of Oncogenic Biomarker Market	225
10.1.1	High demand and Unmet Need Enhances the Global Biomarker Market	225
10.1.2	Biomarkers are Highly Specific Diagnostic and Prognostic Clinical Tools	225
10.1.3	Increasing Cancer Prevalence Globally	226
10.1.4	FDA Support Increases Biomarker Development	226
10.1.5	More Streamlined Clinical Trials	227
10.1.6	Significant Growth of High-Impact Oncogenic Biomarker Research	227
10.1.7	Advancements in Discovery Technologies	227
10.2	Challenges of the Oncogenic Biomarker Market	228
10.2.1	Variability of Biomarkers within Different Cancer Subtypes	228
10.2.2	Integration of Genomics and Biomarker Diagnostics into the Healthcare System	228
10.2.3	Ethical Considerations	228
10.3	Restraints of the Cancer Biomarker Market	229
10.3.1	Initial Investment into Biomarker Discovery and Development	229
10.3.2	Are Biomarkers Profitable for Smaller Companies?	229
10.4	Opportunities for the Cancer Biomarker Market	230
10.4.1	Personalized Medicine Market Opportunities	230
10.4.2	Companion Diagnostics	230

Benefits of Investing in our Cutting-Edge Reports

Clients receive **complementary content*** with mid-level and enterprise wide licences

Post-sale **complementary consultation** with senior expert analyst is included

Use of tables and figures in your own reports and presentations is permitted

Each report provides **straight-talking** strategic analysis & sector intelligence

All reports are **updated each quarter** to give you the most up-to-date information

WE WANT TO MAXIMIZE YOUR BUSINESS POTENTIAL

* Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale

List of Figures

Figure 2.1: Global Cancer Statistics – Key Facts	20
Figure 2.2: Number of Lung, Breast and Colorectal Cancer Diagnoses Globally, 2012	21
Figure 2.3: Percentage of Lung, Breast and Colorectal Cancer Diagnoses Globally, 2012	21
Figure 2.4: Number of Lung, Liver and Stomach Cancer Deaths Globally, 2012	22
Figure 2.5: Percentage of Lung, Liver and Stomach Cancer Deaths Globally, 2012	22
Figure 2.6: Global Cancer Incidence, Men 2012 (per 100,000)	23
Figure 2.7: Global Cancer Mortality, Men 2012 (per 100,000)	23
Figure 2.8: Global Cancer Incidence, Women 2012 (per 100,000)	24
Figure 2.9: Global Cancer Mortality, Women 2012 (per 100,000)	24
Figure 2.10: Number (Millions) of Smokers (Men and Women) in China, Russia, India, the UK and USA	25
Figure 2.11: Incidence and Mortality Rates of Global Lung Cancer (Male and Female)	27
Figure 2.12: Incidence and Mortality Rates of Global Colorectal Cancer (Male and Female)	30
Figure 2.13: Incidence and Mortality Rates of Global Prostate Cancer	32
Figure 2.14: Global Incidence and Mortality of All Cancer Types (excl non-melanoma skin-cancer) per 100,000, Male and Female	34
Figure 2.15: Combined Global Prostate, Breast, Colorectal, Lung and Bladder Cancer Incidence and Mortality by Male and Female	35
Figure 2.16: Cancer Deaths in Women, Globally according to Cancer Type	36
Figure 2.17: Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer Globally	36
Figure 2.18: Top Three Cancers Leading to Global Economic Burden of Cancer (\$ Billion)	40
Figure 2.19: Top 20 Cancers in the USA, Adults (Male and Female)	41
Figure 2.20: Top Adult Male Cancers, USA, Estimated Five Year Prevalence 2012-2017	42
Figure 2.21: Top Adult Female Cancers, USA, Estimated Five Year Prevalence 2012-2017	42
Figure 2.22: US Age Adjusted Cancer Death Rates Per 100,000 (Male) by Cancer Type, 1930-2009	43
Figure 2.23: US Age Adjusted Cancer Death Rates Per 100,000 (Female) by Cancer Type, 1930-2009	43
Figure 2.24: Incidence and Mortality of Lung Cancer (Male) Patients in the Americas	44
Figure 2.25: Incidence and Mortality of Lung Cancer (Female) Patients in the Americas	45
Figure 2.26: Incidence and Mortality of Colorectal Cancer (Male and Female) Patients in the Americas	47
Figure 2.27: Colorectal Cancer Incidence Rates (per 100,000) by Race/Ethnicity and Sex, USA	48
Figure 2.28: Colorectal Cancer Death Rates (per 100,000) by Race/Ethnicity and Sex, USA	48
Figure 2.29: Colorectal Cancer Incidence Rates (per 100,000) by State, USA	48
Figure 2.30: Colorectal Cancer Mortality Rates (per 100,000) by State, USA	49
Figure 2.31: Adults Aged 50–75 Years (%) That are Up-to-Date with Colorectal Test Screening, by State, United States	49
Figure 2.32: Incidence and Mortality of Prostate Cancer (Male) Patients in the Americas	51
Figure 2.33: Incidence and Mortality of Melanoma (Male and Female) Patients in the Americas	53
Figure 3.1: Integration of Oncogenic Biomarker Data to Cancer Diagnosis and Clinical Decisions	55
Figure 3.2: Influence of Biomarker Market on R&D, Molecular Diagnostics, Emerging Diagnostics and Independent Clinical Molecular Diagnostic Services	55
Figure 3.3: Biomarker Discovery to Clinical Assay Development and Validation Process	56
Figure 3.4: Mass Spectrometry Based Technologies in Oncogenic Biomarker Discovery	57
Figure 3.5: Principles of Enzyme-Linked Immunosorbant Assay (ELISA)	63
Figure 4.1: The Different Phases of Fit-For-Purpose Biomarker Validation	74
Figure 4.2: Biomarker Validation Using ELISA Technique	75
Figure 5.1: Frequency of Genetic Mutation by Cancer Subtype	77
Figure 5.2: Oncogenic Biomarker P53 Signalling Pathway: Activators, Effectors, Inhibitors and Cellular Outcomes	79
Figure 5.3: P53 Somatic Mutation Prevalence by Tumor Site	80
Figure 5.4: P53 Germline Mutation Prevalence by Tumor Site	81

Figure 5.5: EGFR Signalling Pathways and Potential Biomarker Proteins	85
Figure 5.6: Clinically Validated Resistance Mechanisms to EGFR Inhibitors	86
Figure 5.7: BRCA Mutation Increases the Risk of Breast and Ovarian Cancer	89
Figure 5.8: Proactive Cancer Management and Preventative Measures Reduces the Risks of Developing BRCA-associated Breast and Ovarian Cancer	89
Figure 6.1: Economic Burden of Cancer in the US, Direct and Indirect Costs (\$ billion)	101
Figure 6.2: Economic Burden of Cancer in the US, Direct and Indirect Costs (%)	102
Figure 6.3: Global Biomarker Market Worth (Billions) and CAGR (%) 2011-2018	103
Figure 6.4: Oncogenic Biomarker Share of Total Personalized Medicine Biomarker Space	104
Figure 6.5: Oncogenic Biomarker Market Distribution by Cancer Type	104
Figure 6.6: Global Cancer Profiling Technology Market Worth (Billions) and CAGR 2013-2018	105
Figure 6.7: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018	106
Figure 6.8: Global Oncology Biomarker Market as a Percentage of Total Biomarker Market 2013-2018	108
Figure 6.9: USA Cancer Biomarker Market Share Compared to Global Biomarker Market 2013-2018	109
Figure 6.10: Number of Peer-Reviewed Publications in the Area of Oncology Biomarker Research 2008-2013	110
Figure 6.11: Number of Peer-Reviewed Publications ion Oncogenes within Oncogenic Biomarker Research 2008-2013	110
Figure 6.12: Number of Peer-Reviewed Publications on MicroRNAs Within Oncology Biomarker Research 2008-2013	111
Figure 6.13: Number of Peer-Reviewed Publications on Epigenetic Modifications Within Oncology Biomarker Research 2008-2013	111
Figure 6.14: Number of Peer-Reviewed Publications by the National Cancer Institute Within Oncology Biomarker Research 2008-2013	112
Figure 6.15: Number of Peer-Reviewed Publications on Tumor Suppressor Genes Within Oncology Biomarker Research 2008-2013	112
Figure 6.16: Number of Peer-Reviewed Publications on incRNA Within Oncology Biomarker Research 2008-2013	113
Figure 6.17: Most Popular Proteomic and Genomic Technologies Performed by End-Users	114
Figure 7.1: Celldex Therapeutics Product Pipeline	123
Figure 7.2: Single Cell Network Profiling (SCNP) Technology by Nodality	129
Figure 7.3: Developed Functional Assays that Nodality has explored using new SCNP Technology	129
Figure 8.1: HER2 Testing Algorithm for Breast Cancer	133
Figure 8.2: HER2 Cellular Signalling	133
Figure 8.3: QUICKFACTS: Herceptin – Mechanism of Action	134
Figure 8.4: Illumina New Generation Sequencing Technology Workflow Station	157
Figure 8.5: Genomic Health Studies Used in the Development of the DCIS Score Algorithm	160
Figure 8.6: Genomic Health Gene Panel Used for Oncotype DX Breast Cancer Test	161
Figure 8.7: Genomic Health Gene Panel Used for Oncotype DX Colon Cancer Test	161
Figure 8.8: Genomic Health Oncotype DX Prostate Cancer Test Development Process	162
Figure 8.9: Genomic Health Gene Panel Used for Oncotype DX Prostate Cancer Test	162
Figure 8.10: OriGene’s TissueScan Cancer cDNA Array Sequence of Analysis	169
Figure 9.1: Private Funding Gained by 23andMe 2007-2012	178
Figure 9.2: Affymetrix Revenue by Business Segment (Percentage), 2013	184
Figure 9.3: Affymetrix Revenue by Business Segment (Percentage), 2013	184
Figure 9.4: Affymetrix Total Revenue 2007-2013	185
Figure 9.5: Affymetrix Revenue by Product Division – Consumables, Instruments 2010-2012	186
Figure 9.6: Affymetrix Core Product Sales – Gene Expression, Genetic Analysis & Clinical Applications and Life Science Reagents, 2011-2012	186
Figure 9.7: Affymetrix Revenue Derived from Outside the US, 2009-2012	187

Figure 9.8: Affymetrix Revenue Derived from the US, 2009-2012	187
Figure 9.9: Affymetrix Net Loss, 2009-2012	188
Figure 9.10: Affymetrix Research and Development Funding, 2009-2012	188
Figure 9.11: Affymetrix Revenue Generated within USA (Percentage) 2010-2012	189
Figure 9.12: Astex Pharmaceuticals Priority Pipeline Products SGI-110 and AT13387 by Indication, Clinical Phase and Timeline	190
Figure 9.13: Astex Pharmaceuticals Revenue Generated 2008-2012	191
Figure 9.14: Astex Pharmaceuticals Net Income 2009-2012	191
Figure 9.15: Atossa Genetics Total Revenue (US\$) 2011, 2012	194
Figure 9.16: Atossa Genetics Revenue (US\$) Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012	194
Figure 9.17: Atossa Genetics Percentage Revenue Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012	195
Figure 9.18: Quest Diagnostics Revenue (\$ Billions) 2008-2013	201
Figure 9.19: Quest Diagnostics Operating Revenue (\$ Billions) 2008-2013	202
Figure 9.20: Quest Diagnostics Net Income (\$ Billions) 2008-2013	202
Figure 9.21: Celera (Quest Diagnostics) Historic Revenue Generated 2008-2010	203
Figure 9.22: Celera (Quest Diagnostics) Historic Gross Margin Generated 2008-2010	203
Figure 9.23: Celera (Quest Diagnostics) Historic Revenue Generated– Laboratory Services and Products 2008-2010	204
Figure 9.24: Celera (Quest Diagnostics) Historic Revenue (%) Generated by Distribution Agreement with Abbott 2008-2010	205
Figure 9.25: Celera (Quest Diagnostics) Historic Research and Development Spending 2008-2010	206
Figure 9.26: deCode Genetics Historic Net Loss Incurred 2004-2008	208
Figure 9.27: Foundation Medicine International Sales – FoundationOne 2012-2013	208
Figure 9.28: Foundation Medicine International Revenue 2012-2013	209
Figure 9.29: Foundation Medicine Geographical (USA) Revenue Percentage 2011-2013	210
Figure 9.30: Illumina Revenue Generated (\$ Billions) 2010-2013	212
Figure 9.31: Illumina Net Income Generated (\$ Billions) 2010-2013	212
Figure 9.32: Genomic Health Oncotype DX Test Revenue 2008-2013	214
Figure 9.33: Myriad Revenue Generated 2007-2014	216
Figure 9.34: Operating Income Generated by Myriad 2007-2013	217
Figure 9.35: Myriad Revenue Generated by Molecular Diagnostic Testing and Companion Diagnostic Services, 2012-2013	217
Figure 9.36: Future Molecular Diagnostic Pipeline of Myriad	218
Figure 9.37: Customer Profile of Qiagen – Percentage of Net Sales 2012/2013	222
Figure 9.38: Qiagen Global Net Sales 2007-2013	223
Figure 9.39: Qiagen Operating Income 2007-2013	223
Figure 9.40: Qiagen Global Net Income 2007-2013	224

List of Tables

Table 2.1: QUICKFACTS- Top Five Most Frequent Cancers in Men and Women, Globally	20
Table 2.2: Main Clinical Stages of Lung Cancer	26
Table 2.3: Current Therapeutic Options for Lung Cancer	27
Table 2.4: QUICKFACTS- Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer per Country, Worldwide	37
Table 2.5: Risk Factors of Colorectal Cancer	47
Table 3.1: Important Advantages of Using Biomarkers as Diagnostic Tools	54
Table 3.2: Biomarkers in Early Drug Development and Decision Making	54
Table 3.3: Biomarkers in Later Drug Development and Decision Making	55
Table 3.4: Functions of Biomarkers within the Healthcare Setting	55
Table 3.5: Ideal Attributes of Clinical Oncogenic Biomarkers	56
Table 3.6: Main Technologies Used in the Discovery of Biomarkers	56
Table 3.7: Proteomic Technologies Used in Biomarker Discovery	57
Table 3.8: Types of Cancer Aided Diagnostically by Mass Spectrometry	58
Table 3.9: Recommendations for Use of MALDI-TOF MS in Cancer Diagnostics	60
Table 3.10: Metabolomic Discovered Potential Oncogenic Biomarkers	62
Table 3.11: Cancer Biomarkers in Clinical Practice Using ELISA Technology	64
Table 3.12: Putative Cancer Biomarkers that can be Detected using ELISA Technology	64
Table 3.13: Advantages of Selected (Multiple) Reaction Monitoring Technique in Biomarker Discovery	67
Table 3.14: Major Advantages of Microarray Assays	67
Table 3.15: Applications of Microarrays	67
Table 3.16: Applications of Microarray Technology in Cancer Diagnostics	68
Table 3.17: Commercially Available Microarray Kits for Cancer Diagnostics	68
Table 3.18: Recommendations for Use of Microarrays in Cancer Diagnostics	69
Table 3.19: Digital PCR in Comparison to Real-time PCR and Traditional PCR	70
Table 3.20: Advantages of Digital PCR	70
Table 3.21: Applications of Digital PCR	70
Table 4.1: Current General Classes of Biomarker Assay as Defined by the American Association of Pharmaceutical Scientists	73
Table 4.2: Comparison of Validative Properties of Different Bioassay Classes	73
Table 5.1: Catalogue of Somatic Mutations in Cancer (COSMIC) Current Statistics	77
Table 5.2: Important Genetic Oncogenic Biomarkers and Their Application in Treatment	78
Table 5.3: P53 Somatic Mutation Prevalence by Tumor Site	80
Table 5.4: P53 Germline Mutation Prevalence by Tumor Site	81
Table 5.5: List of P53 Down-regulated Gene Targets	82
Table 5.6: List of P53 Up-regulated Gene Targets	82
Table 5.7: Positive Regulators of Epidermal Growth Factor Receptor (EGFR) Activity	84
Table 5.8: Types of Cancer Associated with EGFR Over-expression	85
Table 5.9: EGFR-Activating and Resistance Mutations Identified in Lung Adenocarcinoma	86
Table 5.10: Current Next Generation EGFR Inhibitors that Target the T790M Mutation	87
Table 5.11: Prevalence of Deleterious Mutations in <i>BRCA1</i> and <i>BRCA2</i> Genes	87
Table 5.12: Prevalence of Deleterious Mutations in <i>BRCA1</i> and <i>BRCA2</i> in Individuals of Ashkenazi Ancestry	88
Table 5.13: Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)	89
Table 5.14: PARP Inhibitors in Late-Stage Development	90
Table 5.15: Novel and Potential Biomarkers Within the PARP-Inhibitor Response Pathway	92
Table 5.16: Negative Regulators of PTEN Protein Expression	92
Table 5.17: Positive Regulators of PTEN Protein Expression	92
Table 5.18: ATM Molecular Targets and Protein Interactions	94
Table 5.19: Key Facts Regarding MiR-17/92 Cluster	95

Table 5.20: Expression Levels of Individual MiR-17/92 Biomarkers in Cancer, Cardiovascular Disease, Alzheimer's, Multiple Sclerosis, Aging and Normal Development	96
Table 5.21: Functional and Validated Positive Regulators of MiR-17/92	98
Table 5.22: Functional and Validated Negative Regulators of MiR-17/92	99
Table 5.23: Potential Regulators of MiR-17/92	99
Table 5.24: Cellular Signal Transduction Pathways Regulated by the MiR-17/92 Cluster	99
Table 5.25: Specific Cell Death Protein Targets of the MiR-17/92 Cluster	100
Table 5.26: Specific Cell Cycle Arrest Protein Targets of the MiR-17/92 Cluster	100
Table 5.27: Specific Cell Cycle Regulation Protein Targets of the MiR-17/92 Cluster	100
Table 5.28: Specific Heart and Lung Development Protein Targets of the MiR-17/92 Cluster	100
Table 5.29: Specific Cell Proliferation Protein Targets of the MiR-17/92 Cluster	100
Table 6.1: Global Biomarker Market Worth (Billions) and CAGR (%) 2011-2018	102
Table 6.2: Main Diagnostic Areas Within Oncology Biomarker Market	103
Table 6.3: Future Diagnostic Areas With High Potential Within Oncology Biomarker Market	103
Table 6.4: Global Cancer Profiling Technology Market Worth (Billions) and CAGR 2013-2018	105
Table 6.5: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018	106
Table 6.6: USA Cancer Biomarker Market Share Compared to Global Biomarker Market 2013-2018	108
Table 6.7: Main Sub-Sets of Oncogenic Biomarker Research Published 2008-2013	109
Table 7.1: Patent Listing of Affymetrix Array technology	117
Table 7.2: Patent Listing of Affymetrix Genotyping Technology	117
Table 7.3: Patent Listing of Affymetrix Expression and Profiling Technology	118
Table 7.4: Advantages of Astex Pharmaceuticals Pyramid™ Fragment-Drug-Discovery System	119
Table 7.5: Astex Pharmaceuticals Pipeline Portfolio	120
Table 7.6: Astex Pharmaceuticals Pipeline Portfolio Funded Completely by Partner Companies	120
Table 7.7: Potential Business Partnerships of Celldex Therapeutics	123
Table 7.8: Illumina Core Technologies	125
Table 7.9: Illumina Core Technology Applications	125
Table 7.10: Illumina Instrument Product Portfolio	125
Table 7.11: Illumina Assay Product Portfolio	125
Table 7.12: Genetic Test Panel Available from Genelex for Research Institutions and Clinical Trials	126
Table 7.13: Pre-Clinical, Clinical and Commercial Applications of SCNP by Nodality	130
Table 7.14: Qiagen Timeline of Events, 1994-2012	131
Table 7.15: QUICKFACTs - Range of Product Groups from Qiagen	132
Table 8.1: Types of Diagnostic Tests Available to Determine HER2 Status in Breast Cancer Patients	133
Table 8.2: Validated HER2 Tests for Cancer	134
Table 8.3: Advantages and Limitations of IHC HER2 testing applied to breast cancer	134
Table 8.4: In-Situ Hybridization Determination of HER2 Expression by PathVysion® and HER2 FISH pharmDx™	134
Table 8.5: HER2 CISH Determination	135
Table 8.7: Validated FISH Kits for HER2 Testing in Breast Cancer	135
Table 8.8: Validated SISH Kits for HER2 Testing in Breast Cancer	135
Table 8.9: Validated CISH Kits for HER2 Testing in Breast Cancer	135
Table 8.10: Advantages and Limitations of ISH Techniques Applied to HER2 Testing in Breast Cancer	135
Table 8.11: 23andMe Disease Risk Genetic Test Panel	136
Table 8.12: 23andMe Carrier Status Genetic Test Panel	137
Table 8.13: 23andMe Drug Response Genetic Marker Test Panel	138
Table 8.14: 23andMe Genetic Traits Test Panel	138
Table 8.15: QUICKFACTs - Product Overview of Affymetrix	139
Table 8.16: Microarray Products by Affymetrix	140
Table 8.17: Affymetrix Research Services Laboratory (ARSL) Premier Services	140
Table 8.18: Genetic Applications of Axiom® Technology by Affymetrix	140

Table 8.19: Clinical Diagnostic Test Kits Available from Ambry Genetics	143
Table 8.20: Ambry Genetics Cancer Test Portfolio and Genetic Biomarkers	143
Table 8.21: Ambry Genetics Comprehensive List of Genetic Tests by Disease and Genetic Biomarkers	143
Table 8.22: Ambry Genetics BRCA1/2 Breast Cancer Test Portfolio	149
Table 8.23: Ambry Genetics Genome Sequencing Services	149
Table 8.24: Ambry Genetics New Generation Sequencing Platform Portfolio & Applications	149
Table 8.25: Range of Small Molecule Therapeutics Available from Astex Pharmaceuticals	150
Table 8.26: Genetic Tests Available from BHL/Celera	152
Table 8.27: Panel of BHL Clinical Diagnostic Tests	152
Table 8.28: Genetic Diagnostic Tests Available from deCODE Genetics	153
Table 8.29: Disease States that are Included in the deCODE Complete™ Genetic Screen	154
Table 8.30: Panel of Diseases Screened for in the deCODE Cancer™ Test	154
Table 8.31: deCODE Genetics Genotyping and Sequencing Service	154
Table 8.32: deCODE Genetics Data Management, Protection and Storage Service	154
Table 8.33: deCODE Genetics Sequence Imputation and Data Analysis Service	155
Table 8.34: FoundationOne Assay Technical Specifications	155
Table 8.35: FoundationOne Assay Oncogenic Gene Portfolio	155
Table 8.36: FoundationOne Heme Assay Oncogenic Gene Portfolio	156
Table 8.37: Illumina HiSeq 2500/1500 Performance Parameters	157
Table 8.38: Illumina HiSeq 2000/1000 Performance Parameters	157
Table 8.39: Genome Analyzer Iix Performance Parameters	158
Table 8.40: Illumina MiSeq Product Specifications	158
Table 8.41: Illumina HiScanHQ Product Specifications	159
Table 8.42: Illumina HiScan and iScan Array Product Applications	159
Table 8.43: Illumina HiScan and iScan Array Kits	159
Table 8.44: Predictive Genetic Tests Available from Myriad	163
Table 8.45: Services offered with BRACAnalysis® Testing from Myriad	163
Table 8.46: Advantages of BRACAnalysis® Testing	163
Table 8.47: QUICK FACTS- Prevalence of Deleterious Mutations in <i>BRCA1</i> & <i>BRCA2</i> Genes	164
Table 8.48: QUICK FACTS- prevalence of deleterious mutations in <i>BRCA1</i> and <i>BRCA2</i> in individuals of Ashkenazi Ancestry	164
Table 8.49: QUICK FACTS- Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)	165
Table 8.50: QUICKFACTS- BRACAnalysis® Panel of Assays	165
Table 8.51: COLARIS® Test Range by Myriad	166
Table 8.52: COLARIS AP® Test Range by Myriad	166
Table 8.53: MELARIS® Test Range from Myriad	166
Table 8.54 Personalized Medicine Tests from Myriad	167
Table 8.55: The Prolaris Score for Prostate Cancer	167
Table 8.56: OnDose® Testing Procedure from Myriad	168
Table 8.57: OriGene TissueScan cDNA Array Oncology Product Portfolio	169
Table 8.58: Qiagen Genotyping Products for Sample Collection, stabilization and Storage	171
Table 8.59: Qiagen Genotyping Products for Genomic DNA Isolation and Purification	171
Table 8.60: Qiagen Genotyping Products for PCR Based Genotyping Analysis	171
Table 8.61: Qiagen Products for Genotyping Analysis	174
Table 8.62: Qiagen Genotyping Products for PCR Detection	174
Table 8.63: Qiagen Assays for Genetic Analysis	174
Table 8.64: Qiagen Pyrosequencing-Based Genetic Analysis Products	174
Table 8.65: Specifications and Features of Qiagen's QIASymphony and QIASymphony RGQ	175
Table 9.1: Drug Classes Investigated by 23andMe Using Genome Wide Association Studies	179
Table 9.2: Acquisition Profile of Affymetrix	181
Table 9.3: Genetic Applications of Axiom® Technology by Affymetrix	181
Table 9.4: Diversified Business Units of Affymetrix	181
Table 9.5: Affymetrix AgBio Microarray Portfolio	183

Table 9.6: BioMerieux Immunodiagnostic Product Portfolio	195
Table 9.7: BioMerieux Microbiology Product Portfolio	196
Table 9.8: BioMerieux Molecular Diagnostic Product Portfolio	198
Table 9.9: Celera (Quest Diagnostics) Historic Operating (Loss) (US\$) – Laboratory Services and Products 2008-2010	204
Table 9.10: Diagnostic Test Product Categories Manufactured by BHL/Celera and Exclusively Distributed by Abbott	204
Table 9.11: Celldex Therapeutics R&D Expenses (\$) 2010-2012	207
Table 9.12: Price Listing of Genelex Familial Genetic Tests	213
Table 9.13: Myriad - Core Business Decisions and Impact on Industry	217
Table 9.14: Future Test Portfolio of Myriad	218
Table 9.15: Nodality’s Single Cell Network Profiling (SCNP) Technology as a Systems Based Biology Approach to Drug Discovery and Validation	219
Table 10.1: Drivers of the Oncogenic Biomarker Market	227
Table 10.2: Integration of Genomics and Biomarker Diagnostics into the Healthcare System	228
Table 10.3: Challenges of the Cancer Biomarker Market	228

1.0 Executive Summary

“GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)” by Kelly Scientific Publications is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.

One of the most important aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.

1.1 Objectives of Report

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by **280 tables & figures over 232 pages**. This report is presented as follows:

- By **Company** (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH)
- By **Geography** (Global, US)
- By **Sub-market** (Global Biomarker Market, Cancer Biomarker Market, Global Cancer Profiling Technology Market)

A wealth of **financial data & business strategy information** is provided including:

- Up-to-date company financials, sales & revenue figures
- Revenue and market forecasts up to 2018
- Business model strategies for diagnostic, pharmaceutical and biotechnology companies
- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
- Comprehensive account of company product financials, portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
- Top fastest growing market segments and emerging opportunities
- Top pharmaceutical companies within the cancer biomarker market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top companies
- Approved biomarker companion diagnostic tests

- High demand and Unmet Need Enhances the Global Biomarker Market
- FDA Support Increases Biomarker Development
- More Streamlined Clinical Trials
- Significant Growth of High-Impact Oncogenic Biomarker Research
- Advancements in Discovery Technologies
- Challenges of the Oncogenic Biomarker Market
- Variability of Biomarkers within Different Cancer Subtypes
- Integration of Genomics and Biomarker Diagnostics into the Healthcare System
- Ethical Considerations

This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

- 23andMe
- Affymetrix
- Ambry Genetics
- Astex Pharmaceuticals
- Atossa Genetics
- BioMerieux
- CuraGen
- Celera Corporation (Quest Diagnostics)
- Celldex Therapeutics
- deCode Genetics (Amgen)
- Foundation Medicine
- Illumina
- Genelex

- Genomic Health
- Myriad
- Nodality
OriGene Technologies
- Randox
- Qiagen

1.2 Data Sources and Methodology

The project leader and author of this research obtained a Ph.D. in Medicine from the Royal College of Surgeons in Ireland, following completion of a M.Sc. in Biotechnology (NUIG) and an honours degree in Biochemistry from Trinity College Dublin. She has extensive experience in genetics, biomarker and pharmacogenomic research and development and has conducted post-doctoral studies and lecturing in Trinity College Dublin. With many years of medical writing and publishing the author also has extensive experience and knowledge of molecular biology, immunology, bioinformatics and diagnostic testing. As a pharma/biotech industry analyst she has significant expertise in laboratory diagnostic testing and instrument and reagent development technology.

Sources of information for this report were collected and compiled from company specific corporate websites, annual reports, press-releases, international scientific and medical journals and news and research reports. Graphical and numerical data have been referenced and sourced accordingly. Specific websites were consulted and referenced throughout the completion of this report including that of the Food and Drug Association (www.fda.gov), the National Cancer Institute and other government agencies worldwide. Kelly Scientific Publications has used the most recent statistical and numerical data available. The most reliable of data sources were used in the production of this report, however we cannot guarantee complete accuracy or completeness from secondary information sources.

1.3 Key Findings and Observations

1.3.1 What Makes Cancer Biomarkers so Important for the Healthcare Industry?

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.

One of the most important aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine.

Biomarkers offer significant potential in advancing modern medicine with regards to improving patient diagnosis and treatment options. As many biomarkers are of genetic origin, they can also be used as predisposition markers. Other advantages of these molecular tools include the stratification of patient populations and an increased drug specificity to maximize efficacy and minimize toxicity. Therapies will become more specific as a result of using biomarkers as diagnostic tools, and this will in turn ensure that patients are more responsive to treatment without experiencing un-necessary adverse effects

1.3.2 What Technologies are Used to Identify Novel Biomarkers?

The main technologies that are used to discover biomarkers include bioinformatics, genomics, next generation sequencing, proteomics, nanobiology, systems biology and also the use of stem cells. This report gives a comprehensive analysis of the most important techniques used in industry and R&D today, and reveals which technologies hold the most promise within the market. The report also delves into the complicated practice of biomarker validation and assesses the different phases of validation – from identification to quality control monitoring.

Table 1: Main Technologies Used in the Discovery of Biomarkers

Genomics
Next Generation Sequencing
Bioinformatics
Proteomics
Metabolomics
Nanobiology
Systems Biology
Imaging Technologies
Stem Cells

1.3.3 Increase in Cancer Prevalence is Propelling the Oncogenic Biomarker Market

Over 32 million people globally are living with cancer in 2014. According to Cancer Research UK, over 14.1 million new cancer cases were diagnosed in 2012. Of these, 7.4 million men and 6.6 million women were diagnosed. The most common cancers reported are:

- Lung
- Breast
- Colorectal (bowel)
- Prostate


These four cancer subtypes account for 40% of total. In 2012 alone, 8.2 million people died from cancer globally, with 60% of these occurring in less developed regions. Lung, liver, stomach and bowel cancers were responsible for the majority of these deaths, with lung cancer the most significant killer at 20% or 1.59 million deaths. Liver cancer killed 0.8 million in 2012, with stomach cancer killing 0.7 million.

Cancer is the second most common cause of death in the US today, killing one in every four. The National Cancer Institute estimates that 13.7 million Americans have had cancer in the past or are currently suffering from this disease. Recent statistics from the American Cancer Society (ACS) estimated over 580,000 US citizens died from cancer in 2013. Of these, 174,100 deaths could have been prevented. The World Cancer Research Fund estimated that up to 33% of US cancers in 2013 were attributed to lifestyle factors.

Table 2: Top Five Most Frequent Cancers in Men and Women, Globally

Men	Women	Total
Lung	Breast	Lung
Prostate	Colorectum	Breast
Colorectum	Cervix uteri	Colorectum
Stomach	Lung	Stomach
Liver	Stomach	Prostate

Figure 1: Percentage of Lung, Breast and Colorectal Cancer Diagnoses Globally




1.3.4 Global and US Economic Impact of Cancer

GLOBOCAN estimates that by 2025, 19.3 million new cancer cases annually will be diagnosed. This will be primarily due to an aging population. Furthermore, the majority of these cases will occur in less developed regions of the world.

The American Cancer Society estimates that the global economic burden of cancer is in the region of \$ [REDACTED] annually. This is [REDACTED] % of worldwide GDP figures. The top cancers that contribute to this economic burden are lung, colorectal and breast cancer, costing over \$ [REDACTED], \$99 billion, and \$ [REDACTED] respectively.

The National Institutes of Health (NIH) indicated that the economic burden of cancer in the US is over \$ [REDACTED], annually. This is divided into direct medical costs (\$ [REDACTED]) and indirect mortality costs (\$ [REDACTED]) that includes the cost of lost productivity.

Figure x: Top Three Cancers Leading to Global Economic Burden of Cancer (\$ Billion)



1.3.5 How Cancer Biomarkers are Revolutionizing Cancer Treatment

Breast cancer and the use of Herceptin as treatment is an important example of how biomarker detection saves lives and money. Breast cancer is the second highest frequency of cancer globally with a reported 10.9% of total cancer diagnoses. Herceptin (trastuzumab, Genentech) was FDA approved for use in breast cancer patients in 1998 at a cost of between \$██████ to \$██████ annually. However, subsequent analysis indicated that Herceptin was only effective in 25-30% of women who’s tumour cells over synthesized the protein human epidermal growth factor-2 HER2/Neu.

By 2006 all invasive breast cancer patients were recommended to take the HER2 genetic test to identify if they would respond to Herceptin treatment. A further breakthrough in 2008 occurred when a more efficacious Herceptin formulation was approved. Since 2010, more than 420,000 women have been treated with Herceptin, globally.

Today, over 1.7 million women are diagnosed with breast cancer annually (GLOBOCAN). This is a 20% increase in incidence since 2008 estimates, and 14% increase in mortality rates. In 2012 alone, 522,000 women died of breast cancer, compared to 458,000 deaths in 2008.

Early screening and a highly specific biomarker assay is important in detecting cancer, especially in colorectal and prostate cancers as early symptoms are negligible. The use of biomarker companion diagnostics will not only save payers money, it will also promote more targeted therapeutics – thus providing patients with personalized cancer treatment. This has the added benefit of being more effective and having lower adverse reactions and toxicity profiles. Overall, the use of oncogenic biomarker tests and targeted cancer therapies will revolutionize cancer treatment in the short and longer terms.

1.3.6 What are the most Significant and Strategic Cancer Biomarkers?

This cutting-edge report provides a wealth of information on the current and prospective biomarkers in the cancer field. A comprehensive array of the most significant oncogenic biomarker families are analysed with respect to their mechanism of action, clinical functionality and also current clinical trials and studies that are investigating the following:

- P53 Transcription Factor Oncogenic Mutations
- Epidermal Growth Factor Receptor (EGFR)
- BRCA- Mutant Breast and Ovarian Cancer biomarkers
- PARP-Inhibitors
- PTEN – the Tumour Suppressor Gene
- Ataxia Telangiectasia Mutated (ATM)
- Tmprss2-ERG
- MiR-17/92 Cluster
- Significant Molecular Targets of MiR-17/92

A number of cancer types have developed resistance to targeted therapies, and so this report also identifies current strategies to defeat resistance in certain biomarker types.

1.3.7 Global Biomarker Test Market Analysis


Kelly Scientific Publications estimate that the global biomarker market is currently worth \$████ up from \$████ in 2012. Over the last number of years it has grown at a CAGR of ███%, however this is expected to rise to ███% between 2013 and 2018. By 2018, the global biomarker market is estimated to be worth over \$████.

The global biomarker market is segmented into the following therapeutic areas:

- Oncology
- Cardiology
- Neurology
- Infectious disease (e.g., HIV, TB)
- Renal disorders
- Diabetes
- Arthritis

Detailed analysis of this market is provided within this report. The cancer biomarker market is by far the most established within the biomarker space.


Figure 2: Oncogenic Biomarker Share of Total Personalized Medicine Biomarker Space



1.3.8 Global Cancer Biomarker Market Analysis

As early as 2009, the global cancer biomarker market was worth \$ [redacted] and grew to \$ [redacted] in 2013 with a CAGR of [redacted]%. Over the next five years the market is expected to grow further, by a CAGR of [redacted]% to reach over \$ [redacted] in 2018. It is estimated that by 2018, 30% of cancer patients will have a predictive biomarker assay. Currently, 22% of pipeline therapeutics are being investigated in a subsection of patients defined by using a biomarker assisted assay. The cancer biomarker market has the largest share of the overall biomarker market at [redacted]% in 2013 (\$ [redacted] of \$ [redacted] total). By 2018, the oncology biomarker market is expected to be worth \$ [redacted], compared to \$ [redacted] in total.

Figure 4: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018



There is considerable growth within the oncology biomarker market (█%) due to a number of reasons including:

- Rising prevalence of cancer rates globally
- Increased emphasis on early diagnosis
- Enhanced testing capabilities
- Increased awareness and uptake of high-throughput technologies
- Significant advancements in biomarker research
- Increase in number of targeted oncology therapy clinical trials
- US government initiatives
- Increased healthcare professional awareness
- Increased patient awareness
- Strength of the personalized medicine market
- Strength of the overall biomarker market

This report gives a full analysis of the above points and analyses how they will affect the market. In the near future, the oncology biomarker testing market will see the introduction of new assays entering the space. This is primarily due to the fact that technologies such as next generation sequencing will become more cost effective and affordable. Out-licencing and also the co-development of therapy-specific companion diagnostics will promote the market further. Initially, these assays require high levels of healthcare professional interpretation and they are complex to carry out, however over time these restraints will decrease and targeted biomarker evaluation will be more significantly integrated into the healthcare system

1.3.9 Oncology Biomarker Market Main Industry Players

Competitor analysis of the main and upcoming market players is also included in this detailed report. We include up-to-date financial and business strategy analysis for each company, and also detail of every oncology biomarker assay that they provide. Pipeline portfolios are also included, as are current clinical trials, FDA approvals, business collaborations and mergers. The following companies have been analysed by experts at Kelly Scientific Publications:

- 23andMe
- Affymetrix
- Ambry Genetics
- Astex Pharmaceuticals
- Atossa Genetics
- BioMerieux
- CuraGen
- Celera Corporation (Quest Diagnostics)
- Celldex Therapeutics
- deCode Genetics (Amgen)
- Foundation Medicine
- Illumina
- Genelex
- Genomic Health

- Myriad
- Nodality
- Randox
- Qiagen

1.3.10 Drivers, Restraints, Opportunities and Challenges of the Cancer Biomarker Market

This analyses also provides you with a comprehensive account of the drivers and restraints of the global and US cancer biomarker markets. There is a general high demand for biomarker assays and corresponding targeted therapeutics and also an un-met need in the market space. Clinical trials are supporting market growth as they are more streamlined and increasing FDA and regulatory support is also proving positive. There has been a significant boost in oncogenic biomarker research publications over the last five years, and this is further enhancing R&D budgets and investment opportunities. A number of restraints such as initial investment, sample collection and storage and also regulatory hurdles were also identified. The cancer biomarker market however, has enormous potential not only within the overall biomarker space, but also within the personalized medicine and companion diagnostic markets.